At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 25 enrolled
Drug / intervention
E6011 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Early Phase 2 Clinical Trial of E6011 in Patients With Active Crohn's Disease
In Brief
A Phase 2 clinical trial evaluating E6011 and Placebo for Crohn's Disease. Completed, enrolled 25 participants across 46 sites in 5 countries.
Detailed Summary
The primary purpose of this study is to examine the efficacy and safety of E6011 at 12 weeks after administration by means of double-blind placebo-controlled trial.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCrohn's Disease
CountriesCzechia, Hungary, Japan, Poland, Russia
Collaborators--
Timeline
Phase 2CompletedFinished
20192020202120222023202420252026
First PostedNov 2018
Enrollment StartApr 2019
Primary CompletionMar 2022
Study CompletionApr 2024
TodayJul 2026
First PostedNov 7, 2018
Enrollment StartApr 25, 2019
Primary CompletionMar 16, 2022
Study CompletionApr 3, 2024
TodayJul 2, 2026
Enrollment to primary: 2.9 yearsPosted 7.7 years ago
Interventions
E6011drug
E6011, infusion, intravenously.
Placebodrug
Placebo, infusion, intravenously.